NASDAQ:ATXS Astria Therapeutics Q1 2025 Earnings Report $6.35 -0.27 (-4.02%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Astria Therapeutics EPS ResultsActual EPS-$0.58Consensus EPS -$0.48Beat/MissMissed by -$0.10One Year Ago EPSN/AAstria Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAstria Therapeutics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time4:00PM ETUpcoming EarningsAstria Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Astria Therapeutics Earnings HeadlinesBrokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00July 10, 2025 | americanbankingnews.comAstria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National SummitJuly 7, 2025 | finance.yahoo.com[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.July 16 at 2:00 AM | Crypto Swap Profits (Ad)Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Seeking AlphaJuly 3, 2025 | seekingalpha.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMATXS - Astria Therapeutics Inc Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMSee More Astria Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email. Email Address About Astria TherapeuticsAstria Therapeutics (NASDAQ:ATXS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for endocrine and autoimmune disorders. The company’s research portfolio includes long-acting hormone replacement products, enzyme replacement therapies, and targeted biologics designed to address chronic conditions such as adrenal insufficiency, hypoparathyroidism, and rare autoimmune indications. By leveraging proprietary formulation and delivery platforms, Astria aims to improve patient adherence and therapeutic outcomes compared to existing standards of care. Since its founding in 2010 and public listing on the NASDAQ under the ticker ATXS, Astria has advanced multiple product candidates through preclinical and clinical development. Its lead program, a long-acting adrenocorticotropic hormone analog, recently entered pivotal clinical trials following encouraging Phase 2 results that demonstrated prolonged efficacy and a favorable safety profile. Additional pipeline assets include next-generation parathyroid hormone analogs and enzyme therapies engineered for reduced immunogenicity and enhanced tissue targeting. Headquartered in Boston, Massachusetts, Astria operates a research and development hub in the U.S. and maintains strategic partnerships in Europe and Asia to facilitate global clinical studies and future market access. The company’s leadership team is spearheaded by CEO Dr. Elaine Marshall, a veteran biopharma executive with more than 25 years of experience in product development and regulatory affairs. Astria’s scientific advisory board brings together endocrinologists, immunologists, and pharmacokinetic experts to guide its translational research efforts and drive toward commercialization.Written by Jeffrey Neal JohnsonView Astria Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Interactive Brokers Group (7/17/2025)PepsiCo (7/17/2025)Cintas (7/17/2025)Netflix (7/17/2025)American Noble Gas (7/17/2025)U.S. Bancorp (7/17/2025)Novartis (7/17/2025)Abbott Laboratories (7/17/2025)Marsh & McLennan Companies (7/17/2025)Taiwan Semiconductor Manufacturing (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
